Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Sigilon Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 0 | Aug 11, 2023 | Direct | ||
Sigilon Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Stock Option (Right to Buy) | 0 | $0.75 | Aug 11, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SGTX | Sigilon Therapeutics, Inc. | Aug 11, 2023 | 2 | -$8.08K | 4 | Aug 11, 2023 | CHIEF FINANCIAL OFFICER |
SGTX | Sigilon Therapeutics, Inc. | Jul 21, 2023 | 2 | $27.8K | 4 | Jul 24, 2023 | CHIEF FINANCIAL OFFICER |
SGTX | Sigilon Therapeutics, Inc. | Feb 28, 2023 | 1 | $0 | 4 | Mar 1, 2023 | CHIEF FINANCIAL OFFICER |
SGTX | Sigilon Therapeutics, Inc. | Feb 18, 2022 | 1 | $88.8K | 4 | Feb 22, 2022 | ACTING CHIEF FINANCIAL OFFICE |
SGTX | Sigilon Therapeutics, Inc. | Jan 3, 2022 | 1 | $197K | 4 | Jan 4, 2022 | VP, HEAD OF FINANCE |
SGTX | Sigilon Therapeutics, Inc. | Sep 30, 2021 | 1 | $0 | 4 | Oct 4, 2021 | VP, HEAD OF FINANCE |
SGTX | Sigilon Therapeutics, Inc. | Jun 14, 2021 | 0 | $0 | 3 | Jun 21, 2021 | VP, Head of Finance |